filgrastim and pegfilgrastim, are primarily used to reduce the incidence of febrile neutropenia (FN) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of many chemotherapy regimens. Patients
Search Results
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Featured Updates to the NCCN Guidelines
Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, and Lenora A. Pluchino
Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials
David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman
R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 11 Trillet-Lenoir V Green J Manegold C
Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Counterpoint
Johan Maertens, Kristel Buvé, and Elias Anaissie
meta-analysis of randomised-controlled trials . Br J Haematol 2005 ; 131 : 22 – 28 . 7. Cornely OA Maertens J Winston DJ . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia . N Engl J Med 2007 ; 356
Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Point
Antonio V. Gonzalez, Andrew J. Ullmann, Nikolaos G. Almyroudis, and Brahm H. Segal
; 34 : 7 – 14 . 2. Segal BH Almyroudis NG Battiwalla M . Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal
Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy
Gary H. Lyman and Jessica Malone Kleiner
– 454 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy . Leuk Lymph 2003 ; 44 : 2069 – 2076 . 3. Lyman GH . Guidelines of
Myeloid Growth Factors
Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, and Michael K. Wong
: reporting practices from randomized clinical trials . J Natl Compr Canc Netw 2003 ; 1 : 440 – 454 . 2 Dale DC . Colony-stimulating factors for the management of neutropenia in cancer patients . Drugs 2002 ; 62 ( Suppl 1 ): 1 – 15 . 3
Growth Factors in Leukemia
Olga Frankfurt and Martin S. Tallman
; 11 : 466 – 478 . 3. Lieschke GJ Grail D Hodgson G . Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization . Blood 1994
HSR19-091: Incidence of Adverse Events Following Use of Different PARP Inhibitors: Systematic Review and Meta-Analysis
Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson
.2%–55.8%), vomiting (33.7%, 29.5%–38.3%), neutropenia (24.7%, 15.3%–37.4%), headache (23.9%, 19.9%–28.4%), and reduced appetite (21.7%, 19.3%–24.3%). Myeloid neoplasms were rare (1.2%, 0.7%–1.9%). Incidence of grade 3 or higher AE was 44.3% (30.2%–59.5%) and often
EPR19-071: Risk of Hematologic Toxicities and Health-Related Quality of Life Events in Patients With Hematologic Malignancies Treated With Ibrutinib: A Combined Analysis of 6 Phase III Trials
Miguel Quirch, Sriman Swarup, Anita Sultan, Wai L. Thein, Zayar M. Oo, Nyein H. Yu, Myo H. Zaw, Donald P. Quick, and Kyaw Z. Thein
.565–1.168; P =.261); neutropenia, 0.956 (95% CI: 0.720–1.268; P =.754); thrombocytopenia, 1.054 (95% CI: 0.450–2.470; P =.904); fatigue, 0.896 (95% CI: 0.761–1.056; P =.192); pyrexia, 1.123 (95% CI: 0.893–1.413; P =.322); and arthralgia, 1.863 (95% CI: 1
The Role of Myeloid Growth Factors in Acute Leukemia
Martha Wadleigh and Richard M. Stone
) Group . Leukemia 2007 ; 21 : 453 – 461 . 33 Kern W Aul C Maschmeyer G . Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and
